Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study

Sanofi (SNY) announced promising Phase 2a results for brivekimig in treating biologic-naïve patients with moderate-to-severe hidradenitis suppurativa (HS). The HS-OBTAIN study demonstrated clinically meaningful improvements in the primary endpoint (HiSCR50) and key secondary endpoints at week 16 compared to placebo, with the drug exhibiting a favorable safety profile and no serious adverse events. These positive findings position brivekimig as a potentially significant pipeline asset for Sanofi in addressing a chronic and debilitating inflammatory skin disease, with full data to be presented at EADV 2025.

Analysis

Sanofi has announced a significant positive development in its immunology pipeline with promising top-line results from the HS-OBTAIN Phase 2a study for brivekimig. The drug demonstrated clinically meaningful improvements over placebo at week 16 in biologic-naïve patients with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin disease with high unmet need. The trial successfully met its primary endpoint—Hidradenitis Suppurativa Clinical Response (HiSCR50)—as well as key secondary endpoints. Crucially, the treatment was reported to be well tolerated with no serious adverse events, a favorable safety profile that is essential for advancing to later-stage trials. While this is not a final approval, these Phase 2a results represent a key de-risking event for this pipeline asset and provide strong proof-of-concept. The forthcoming presentation at the EADV 2025 Congress will be a key catalyst, as the market will scrutinize the full data set to assess the magnitude of clinical benefit and long-term potential.

Key Decisions for Investors

• The positive clinical data for brivekimig strengthens Sanofi's R&D pipeline and provides a potential long-term growth driver in the competitive immunology market, supporting a constructive view on the stock.
• Investors should monitor for the full data presentation at the EADV 2025 congress, as the detailed efficacy and safety results will be critical for validating the drug's commercial potential before making significant capital allocation decisions.
• While this development de-risks a pipeline asset, its direct revenue impact remains contingent on successful Phase 3 trials and regulatory approvals, which are still several years away, and should be factored into valuation models as a long-term catalyst.